Noxopharm (ASX:NOX) said that the holders of its existing convertible notes, with a total aggregate note face value of AU$2.6 million, approved the extension of the maturity date of their convertible notes to Jan. 2, 2027, according to a Tuesday Australian bourse filing.

The noteholders will be paid accrued interest of AU$327,000 in aggregate on the convertible notes in cash for the period ending Jan. 2, 2026, with the interest accruing from Jan. 2, 2026, capitalized daily until maturity.

The extension will allow the company to access rebate funds of around AU$2.8 million from the Australian Federal Government's Research and Development Tax Incentive Scheme for the financial year ended June 30.

It entered into an unsecured loan agreement with 4F Investments, which is owned and controlled by Noxopharm Chairman Fred Bart, for a AU$1.25 million unsecured loan to Noxopharm. Interest will be payable at 12% per annum on the loan capitalized daily until maturity.

The firm's shares fell 5% in recent trading on Tuesday.